Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value
SeekingAlpha23 gün önceCRVS
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
Corvus Pharma (CRVS) Strong Buy: soquelitinib PTCL & atopic dermatitis catalysts, key 2027 readouts, $215M cash to Q2 2028âread now.
SeekingAlpha25 gün önceCRVS
